cis-Element clustering correlates with dose-dependent pro- and antisignaling effects of IL18

Genes and Immunity

Volumn 5, Issue 5, 2004, Pages 354-362

  Leyfer, D ^a   Bond, A ^b   Tworog, E ^b   Perron, D ^b   Maska, S ^b   Brito, A ^b   Kamens, J ^b   Weng, Z ^a,c   Voss, Jeffrey ^b  

^a BOSTON UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Biomedical Engineering Soc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONOCYTE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SENSITIVITY ANALYSIS;

CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-18; MONOCYTES; MULTIGENE FAMILY; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 4344695101     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364099     Document Type: Article

References (33)

1. Robinson D, Shibuya K, Mul A et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997; 7: 571-581.
2. Kohno K, Kataoka J, Ohtsuki T et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158: 1541-1550.
3. Micallef MJ, Tanimoto T, Kohno K et al. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997; 57: 4557-4563.
4. Takeda K, Tsutsui H, Yoshimoto T et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998; 8: 383-390.
5. Kanakaraj P, Ngo K, Wu Y et al. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 1999; 189: 1129-1138.
6. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998; 187: 2103-2108.
7. Kojima H, Aizawa Y, Yanaj Y et al. An essential role for NF-kappa B in IL-18-induced IFN-gamma expression in KG-1 cells. J Immunol 1999; 162: 5063-5069.
8. Puren AJ, Fantuzzi G, Gu Y et al. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101: 711-721.
9. Yoshida A, Kohka Takahashi H, Iwagaki H et al. Essential role of ICAM-1/LFA-1 interaction in synergistic effect of IL- 18 and IL-12 on IFN-gamma production in human PBMC. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 181-186.
10. Schindler H, Lutz MB, Rollinghoff M, Bogdan C. The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J Immunol 2001; 166: 3075-3082.
11. Parnet P, Garka KE, Bonnert TP et al. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem 1996; 271: 3967-3970.
12. Kojima H, Takeuchi M, Ohta T et al. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem Biophys Res Commun 1998; 244: 183-186.
13. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12: 53-72.
14. Adachi O, Kawai T, Takada K et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9: 143-150.
15. Matsumoto S, Tsuji-Takayama K, Aizawa Y et al. Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun 1997; 234: 454-457.
16. Yoshimoto T, Takada K, Tanaka T et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400-3407.
17. Ahn HJ, Maruo S, Tomura M et al. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 1997; 159: 2125-2131.
18. Micallef MJ, Ohtsuki T, Kohno K et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26: 1647-1651.
19. Yoshimoto T, Okamura H, Tagawa YI et al. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997; 94: 3948-3953.
20. Nakahira M, Ahn HJ, Park WR et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002; 168: 1146-1153.
21. Gracie JA, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104: 1393-1401.
22. Takaori-Kondo A, Hori T, Fukunaga K et al. Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling. Biochem Biophys Res Commun 2000; 272: 856-863.
23. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science 1998; 281: 998-1001.
24. Xu LG, Shu HB. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol 2002; 169: 6883-6889.
25. Uren AG, Pakusch M, Hawkins CJ et al. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 1996; 93: 4974-4978.
26. Mehta CR. The exact analysis of contingency tables in medical research. Stat Methods Med Res 1994; 3: 135-156.
27. Cotta CV, Zhang Z, Kim HG, Klug CA. Pax5 determines B versus T cell fate and does not block early myeloid-lineage development. Blood 2003; 30: 30.
28. Kuo CT, Leiden JM. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol 1999; 17: 149-187.
29. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002; 298: 1241-1245.
30. Ohtsuki T, Michallef MJ, Kohno K et al. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 1997; 17: 3253-3258.
31. Okano F, Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res 2000; 20: 3411-3415.
32. Hashimoto W, Osaki T, Okamura H et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 583-589.
33. Kent WJ, Sugnet CW, Furey TS et al The human genome browser at UCSC. Genome Res 2002; 12: 996-1006.